Mental health diagnosis and medication changes after initiation of elexacaftor/tezacaftor/ivacaftor.

Document Type

Article

Publication Date

3-1-2026

Identifier

DOI: 10.1513/AnnalsATS.202505-552OC

Abstract

RATIONALE: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with varied effects on mental health (MH) in people with cystic fibrosis (PwCF). Currently published literature has focused primarily on MH diagnoses/symptoms with ETI as opposed to associated pharmacotherapy.

OBJECTIVES: We sought to evaluate the effect of ETI on MH diagnosis and associated pharmacotherapy in both adult and pediatric PwCF.

METHODS: We conducted a multicenter retrospective study in PwCF who started ETI at 7 accredited cystic fibrosis centers. Primary outcomes were the rate of MH diagnosis and medication use pre- and post-ETI initiation. Secondary outcomes were the rate of MH medication changes and dose adjustments pre- and post-ETI.

MEASUREMENTS AND MAIN RESULTS: Overall, 1046 PwCF were included, with 453 in the "MH group" because they had either an MH diagnosis and/or MH medication use at any time point post-ETI. Mental health medication use and diagnosis both significantly increased from baseline at all time points post-ETI initiation.

CONCLUSIONS: The rate of MH medication use increased significantly from baseline at all time points in PwCF not previously prescribed MH medications, while rate of MH medication use remained consistent for those already on medications pre-ETI.

Journal Title

Ann Am Thorac Soc

Volume

23

Issue

3

First Page

390

Last Page

396

MeSH Keywords

Humans; Cystic Fibrosis; Retrospective Studies; Aminophenols; Male; Benzodioxoles; Female; Quinolones; Adult; Drug Combinations; Indoles; Mental Disorders; Pyrazoles; Adolescent; Child; Pyridines; Young Adult; Chloride Channel Agonists; Pyrrolidines; Mental Health; Quinolines

PubMed ID

41151030

Keywords

CFTR modulator; cystic fibrosis; elexacaftor/tezacaftor/ivacaftor; mental health

Link to Full Text
Library Record

Share

COinS